Cargando…

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study

BACKGROUND: Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaofeng, Zhu, Quan, Liu, Yiqian, Liu, Ping, Yin, Yongmei, Guo, Renhua, Lu, Kaihua, Gu, Yanhong, Liu, Lianke, Wang, Jinghua, Wang, Zhaoxia, Røe, Oluf Dimitri, Shu, Yongqian, Zhu, Lingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023939/ https://www.ncbi.nlm.nih.gov/pubmed/24836053 http://dx.doi.org/10.1371/journal.pone.0095897

Ejemplares similares

Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013)

A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy
por: Qian, Jing, et al.
Publicado: (2016)

MiR‐326/Sp1/KLF3: A novel regulatory axis in lung cancer progression
por: Wang, Rong, et al.
Publicado: (2018)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
por: Zhu, Linggang, et al.
Publicado: (2020)

A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors
por: Liu, Yiqian, et al.
Publicado: (2020)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101)
por: Wang, Rong, et al.
Publicado: (2023)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling
por: Sun, Xiang, et al.
Publicado: (2018)

Merkel cell carcinoma of the thigh: case report and review of the literature
por: Jiang, Wen, et al.
Publicado: (2019)

A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy
por: Ma, Ling, et al.
Publicado: (2022)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer
por: Li, Ke, et al.
Publicado: (2020)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
por: Liu, Jian, et al.
Publicado: (2016)

Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
por: Zhang, Wen, et al.
Publicado: (2020)

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis
por: Xiang, Min, et al.
Publicado: (2020)

JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients
por: Qian, Jing, et al.
Publicado: (2016)

The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data
por: Wang, Yang, et al.
Publicado: (2015)

Efficacy of icotinib in advanced lung squamous cell carcinoma
por: Liang, Shuai, et al.
Publicado: (2018)

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib
por: Shang, Yanhong, et al.
Publicado: (2020)

A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib
por: Huang, Jun, et al.
Publicado: (2020)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
por: Liang, Jun-Li, et al.
Publicado: (2014)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
por: Xu, Jianping, et al.
Publicado: (2016)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1
por: Jin, Shidai, et al.
Publicado: (2018)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
por: Wang, Tao, et al.
Publicado: (2016)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
por: Wang, Xuanxuan, et al.
Publicado: (2018)

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
por: Tan, Xueyun, et al.
Publicado: (2023)

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
por: Zeng, Ziqing, et al.
Publicado: (2020)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
por: Guo, Renhua, et al.
Publicado: (2011)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies
por: Biaoxue, Rong, et al.
Publicado: (2016)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
por: Liu, Tianze, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ikccbr9kuhbmfpaeku7i42r5ai